Immunai, an AI biotech company founded in Israel and headquartered in New York City, has announced the expansion of its collaboration with AstraZeneca, a major player in the pharmaceutical industry. The agreement, which extends through 2027, allows Immunai to receive up to $37.5 million for its contributions to oncology clinical development. This partnership will leverage Immunai's AMICA-OS AI operating system, which integrates clinical immunology data with advanced AI models to support drug development efforts. This marks the third expansion of their collaboration, following previous agreements aimed at applying Immunai's platform across various oncology clinical programs and into inflammatory bowel disease. Jorge Reis-Filho, AstraZeneca's Chief of AI for Science Innovation, emphasized the company's commitment to investing in AI solutions to enhance clinical outcomes. Noam Solomon, CEO of Immunai, noted that the deepening collaboration signifies the platform's effectiveness in generating clinically relevant insights. Immunai specializes in using single-cell genomics and machine learning to study the human immune system and has raised close to $270 million to date, employing more than 170 experts across its offices in New York, Tel Aviv, Prague, and Zurich.